Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Radiotherapy for Malignant Astrocytomas in the Elderly

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase III Treatment Completed 70 and over Other PHRC, P000502 AOM 98071
NCT00430911

Trial Description

Summary

A randomized trial comparing radiotherapy with supportive care in patients aged 70 years or older with newly diagnosed, histologically confirmed anaplastic astrocytoma or glioblastoma, and a Karnofsky performance status > 70.

Eligibility Criteria

Inclusion Criteria:

Glioblastoma and anaplastic astrocytoma, supratentorial, histologically confirmed

Brain CT scan or MRI within 28 days before surgery

Age: 70 years or older

Karnofsky performance status, 70 or more.

Life expectancy over 12 weeks

Informed consent

Exclusion Criteria:

Brain radiotherapy

Chemotherapy

Severe systemic disease

Trial Contact Information

Trial Lead Organizations/Sponsors

Assistance Publique Hopitaux de Paris

jean-yves Delattre, MD

Principal Investigator

Florence Keime-Guibert, MD

Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00430911
Information obtained from ClinicalTrials.gov on March 18, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.